In patients with asthma, the overall response rate to the gold standard treatment, corticosteroids, may be as low as 70%.
Clearly, there is a need to identify treatments that are effective when corticosteroids are not. Malmstrom and colleagues'
study in this issue contributes to other studies that have increased our understanding of the beneficial effects and safety
of leukotriene receptor antagonists.